Trust Signals
Conflicts: FormBlends sells compounded and research-grade peptides. We disclose this and rate evidence honestly, including where our products have weaker data.
Last updated: May 29, 2026.
Standard: Every confidence rating in this article reflects evidence quality, not commercial interest. Claims marked Low or Very Low evidence should not be acted on without clinician guidance.
Key Takeaways
- Semaglutide 2.4 mg weekly produced a mean 14.9% body weight reduction over 68 weeks in the STEP 1 RCT (n=1,961) -- the strongest clinical evidence of any peptide in this category.
- Tirzepatide's SURMOUNT-1 trial (n=2,539) showed a mean 20.9% reduction at the 15 mg dose over 72 weeks, currently the highest published figure for any approved peptide therapy.
- AOD-9604 failed its pivotal phase 3 trial for weight loss; early-phase promise did not replicate at scale.
- GH secretagogues (CJC-1295, ipamorelin) lack direct RCT fat-loss data; their weight-loss rationale relies on extrapolation from GH physiology.
- Most oral "peptide" supplements are degraded in the GI tract and are very unlikely to be bioactive -- the exception is the SNAC-formulated oral semaglutide (Rybelsus), an FDA-approved prescription drug.
What Are the Best Peptides for Weight Loss?
The best peptides for weight loss, ranked by clinical evidence, are semaglutide and tirzepatide -- both FDA-approved GLP-1 receptor agonists with phase 3 RCT data showing double-digit percentage body weight reduction. Research peptides like CJC-1295, ipamorelin, and AOD-9604 have mechanistic rationale but lack the RCT evidence to be ranked alongside them. The evidence gap is not minor; it is categorical.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Evidence Ledger: All Major Peptides Rated
- GLP-1 Receptor Agonists: The High-Evidence Tier
- Mechanism With Numbers: How GLP-1 Agonists Reduce Body Weight
- GH Secretagogues: CJC-1295, Ipamorelin, and GHRP-2
- AOD-9604: What Most Pages Get Wrong
- Chemistry Behind the Rules: Why Peptides Degrade and Why Oral Dosing Fails
- Honest Head-to-Head: Peptides vs. Approved Alternatives
- Operational and Label Literacy: Reading a COA, Reconstitution Math, Degradation Signs
- FAQ
- Sources
What Is the Evidence for Each Weight Loss Peptide?
This table grades every major peptide discussed on this page. Read the confidence column before acting on any claim.
| Peptide | Best Evidence Type | Key Finding | Effect Direction | Confidence |
|---|---|---|---|---|
| Semaglutide (2.4 mg SQ weekly) | Multiple phase 3 RCTs (STEP program) | ~14.9% mean body weight reduction at 68 weeks (STEP 1) | Strong decrease | High |
| Tirzepatide (up to 15 mg SQ weekly) | Phase 3 RCT (SURMOUNT-1) | ~20.9% mean body weight reduction at 72 weeks | Strong decrease | High |
| Liraglutide (3.0 mg SQ daily) | Phase 3 RCT (SCALE Obesity) | ~8% mean body weight reduction at 56 weeks | Moderate decrease | High |
| AOD-9604 | Phase 2 positive; Phase 3 failed | Did not meet primary endpoint in pivotal trial | Null at phase 3 | Low |
| CJC-1295 (with DAC) | Small human PK/PD studies; no weight-loss RCT | Elevates IGF-1 and GH; no direct fat-loss trial | Uncertain | Very Low |
| Ipamorelin | Small human safety/PK studies | Pulsatile GH release; no fat-loss RCT in humans | Uncertain | Very Low |
| GHRP-2 / GHRP-6 | Human PK studies; some body composition data | GH release confirmed; weight effects inconsistent | Weakly positive, inconsistent | Low |
| Tesamorelin | Phase 3 RCTs in HIV-associated lipodystrophy | Reduces visceral fat in HIV patients; not studied in general obesity | Positive (narrow population) | Moderate (HIV lipodystrophy only) |
| BPC-157 | Animal studies only | No human weight-loss data | Unknown in humans | Very Low |
GLP-1 Receptor Agonists: The High-Evidence Tier
Semaglutide and tirzepatide are the only peptides where the word "best" is defensible without heavy qualification. Both are FDA-approved, have replicated phase 3 data, and are prescribed under medical supervision.
Semaglutide (Wegovy)
Semaglutide is a 31-amino-acid GLP-1 analog with a C18 fatty diacid chain that binds albumin, extending its half-life to approximately 7 days -- enabling once-weekly dosing. The STEP 1 trial enrolled 1,961 adults with BMI at least 30 (or 27 with a weight-related comorbidity). At 68 weeks, the 2.4 mg dose arm lost a mean of approximately 14.9% body weight versus approximately 2.4% for placebo. Roughly 86% of the treatment group achieved at least 5% weight loss.
Tirzepatide (Zepbound)
Tirzepatide is a 39-amino-acid dual GIP/GLP-1 receptor agonist. SURMOUNT-1 enrolled 2,539 adults; the 15 mg arm achieved a mean approximately 20.9% weight reduction at 72 weeks. This numerical advantage over semaglutide data has not been tested in a direct randomized head-to-head trial at equivalent doses, so the superiority claim is hypothesis-generating, not proven.
Liraglutide (Saxenda)
An older daily-injection GLP-1 agonist with a shorter half-life of roughly 13 hours. The SCALE Obesity trial showed approximately 8% mean weight loss at 56 weeks. It is less favored now due to daily injection burden and lower efficacy versus newer agents, but has the longest post-approval real-world safety record in this class.
How Do GLP-1 Peptides Actually Reduce Body Weight?
GLP-1 receptors are expressed in pancreatic beta cells, the hypothalamic arcuate and paraventricular nuclei, the brainstem nucleus tractus solitarius, gastric parietal cells, and cardiac tissue. Weight loss occurs through at least three simultaneous pathways:
- Appetite suppression via CNS: GLP-1 receptor activation in the hypothalamus and brainstem reduces orexigenic neuropeptide Y (NPY) and agouti-related peptide (AgRP) signaling while increasing satiety signaling. PET imaging studies in humans show semaglutide crosses the blood-brain barrier and engages hypothalamic regions, though quantitative receptor occupancy data are not yet fully published in public literature.
- Gastric emptying delay: GLP-1 agonists slow gastric emptying, extending the physical sensation of fullness. This effect attenuates somewhat with chronic dosing (tachyphylaxis at the gastric level).
- Glucose-dependent insulin secretion: Enhanced insulin release at postprandial glucose levels contributes to lower postprandial glucose swings, reducing the drive to re-eat.
What this mechanism does NOT prove: Receptor activation data do not tell you the long-term metabolic fate of weight regained after stopping the drug. STEP 4 extension data showed a mean weight regain of roughly two-thirds of lost weight within a year of discontinuation -- a critical fact commodity pages omit.
GH Secretagogues for Fat Loss: What the Data Actually Shows
CJC-1295 is a synthetic GHRH analog; ipamorelin is a GHRP (ghrelin mimetic). The rationale for fat loss is as follows: elevated GH stimulates lipolysis via hormone-sensitive lipase activation and reduces lipoprotein lipase activity in adipose tissue. This is real physiology. The problem is that pharmacologically increasing GH pulses in healthy adults does not reliably translate to the weight loss magnitudes seen with GLP-1 agonists.
A frequently cited 2006 paper by Teichman et al. (J Clin Endocrinol Metab) evaluated CJC-1295 in healthy adults and confirmed sustained GH and IGF-1 elevation -- mean IGF-1 increase of roughly 30-40% above baseline at certain doses -- but this was a pharmacokinetic study, not a weight-loss trial. No published RCT has taken CJC-1295 or ipamorelin through a powered weight-loss endpoint in a general adult population.
Tesamorelin exception: Tesamorelin (Egrifta) is FDA-approved for visceral fat reduction in HIV-associated lipodystrophy and has genuine phase 3 data in that specific population. Extrapolating this to general weight loss in non-HIV patients is unsupported.
AOD-9604: What Most Pages Get Wrong
AOD-9604 is a synthetic fragment of human growth hormone (hGH), specifically the C-terminal region (approximately amino acids 176-191), modified with a tyrosine residue at the N-terminus. Its proposed mechanism is direct lipolytic activity without the metabolic side effects of full-length hGH (no significant IGF-1 elevation at lipolytic doses in animal models).
Most peptide marketing pages present AOD-9604 as a proven fat-loss agent. The actual clinical history is different. Metabolic Pharmaceuticals (Australia) ran a clinical development program through the early 2000s. Phase 2 trials showed modest positive signals. The pivotal phase 3 trial did not demonstrate statistically significant weight loss versus placebo. The program was discontinued, and the compound never received approval as a pharmaceutical. The FDA subsequently recognized AOD-9604 as a GRAS (Generally Recognized As Safe) food ingredient -- a categorization that relates to food safety, not therapeutic efficacy.
The honest conclusion: AOD-9604's mechanism is biologically plausible, early data were intriguing, and it failed the test that matters most. Presenting it as proven is not accurate.
Why Peptides Degrade and Why Oral Peptide Supplements Almost Never Work
This section explains the chemistry behind three rules of thumb so you can make your own judgment on any product.
Rule 1: Most peptides cannot survive oral dosing
Peptides are chains of amino acids linked by amide (peptide) bonds. The GI tract contains multiple proteolytic enzymes -- pepsin (active at gastric pH approximately 1.5-2), trypsin, chymotrypsin, and elastase (active in the small intestine at approximately pH 6-8) -- that are specifically evolved to cleave these bonds. A 30-amino-acid peptide like semaglutide will be fragmented into dipeptides and free amino acids within minutes of hitting gastric fluid. Even if fragments survived, intestinal epithelium has tight junctions that exclude molecules above roughly 500-1000 Da by the paracellular route, and most therapeutic peptides are several thousand daltons.
Oral semaglutide (Rybelsus) works only because it is co-formulated with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), a permeation enhancer that transiently disrupts tight junctions and locally buffers gastric pH around the tablet, protecting the peptide from acid hydrolysis. This is a patented, precisely engineered formulation achieving roughly 1% bioavailability -- and it still requires fasting and a small water volume to work. Generic oral peptides sold as supplements have none of this engineering.
Rule 2: Lyophilized peptides degrade faster than labels suggest if stored incorrectly
Lyophilization (freeze-drying) removes water to slow hydrolytic degradation. However, even dry peptides undergo oxidation (methionine, tryptophan, and cysteine residues are vulnerable), deamidation of asparagine and glutamine residues, and aggregation -- especially at elevated temperatures. Once reconstituted in aqueous solution, degradation accelerates substantially. Bacteriostatic water (0.9% benzyl alcohol) slows microbial growth but does not stop chemical degradation. Specific stability kinetics for unlicensed research peptides are rarely published. The practical rule: use reconstituted peptides promptly, refrigerate at 2-8°C, do not leave at room temperature between doses, and discard any solution that appears cloudy, particulate, or discolored.
Rule 3: The "no cortisol spike" claim for ipamorelin is relative, not absolute
Ipamorelin is promoted as a "clean" GHRP because it shows less cortisol and prolactin stimulation than GHRP-6 in comparative pharmacology studies. This is a real pharmacological distinction -- ipamorelin's selectivity for the ghrelin receptor subtype responsible for GH release is better characterized. But "less cortisol than GHRP-6" does not mean zero cortisol effect, especially at supratherapeutic doses. Context and dose matter.
Honest Head-to-Head: Peptides vs. Real Alternatives
| Treatment | Best Evidence | Mean Weight Loss | Route / Frequency | Regulatory Status (US) | Where Peptide Loses |
|---|---|---|---|---|---|
| Semaglutide 2.4 mg | Phase 3 RCT | ~14.9% (68 weeks) | SQ injection weekly | FDA-approved (Wegovy) | Cost, GI side effects, weight regain on cessation |
| Tirzepatide 15 mg | Phase 3 RCT | ~20.9% (72 weeks) | SQ injection weekly | FDA-approved (Zepbound) | Cost, injection requirement, no head-to-head vs semaglutide |
| Orlistat 120 mg TID | Multiple RCTs | ~3-5% vs placebo | Oral with meals | FDA-approved (OTC and Rx) | Lower efficacy; GI side effects (fecal urgency) |
| Phentermine/topiramate ER | Phase 3 RCT | ~8-10% at highest dose | Oral daily | FDA-approved (Qsymia) | Teratogenicity risk; CV and cognitive effects |
| CJC-1295 + Ipamorelin | Animal data + small human PK | Not established in RCT | SQ injection daily | Research compound only | Loses on every evidence metric; unknown long-term safety |
| AOD-9604 | Phase 3 failed | Not established | SQ injection | Not approved for weight loss | Failed its own definitive trial |
| Intensive lifestyle intervention | Multiple RCTs (Look AHEAD, DPP) | ~5-8% sustained at 1 year | Behavioral | N/A | Lower magnitude than GLP-1s; requires sustained adherence |
The peptide category wins on evidence only at the GLP-1 agonist tier. Every research peptide loses to an approved drug when evidence quality is the criterion.
How to Read a Peptide COA, Reconstitute Safely, and Spot a Degraded Product
Certificate of Analysis: What to demand
| COA Element | What to Look For | Red Flag |
|---|---|---|
| HPLC purity | Greater than 98% for injectable-grade research peptides | No HPLC data, or "greater than 95%" without chromatogram |
| Mass spectrometry (MS) | Confirms molecular weight matches theoretical; rules out wrong peptide | Absent entirely; peptide identity unverified |
| Endotoxin (LAL test) | Less than 1 EU/mg for injectable use is a reasonable threshold | No endotoxin data on injectables -- serious sterility risk |
| Testing laboratory | Named, ideally ISO 17025 accredited third party | In-house testing only, no lab name or accreditation cited |
| Lot/batch number | Should match the vial label | Generic COA not linked to specific lot |
Reconstitution math
A common vial contains 5 mg (5,000 mcg) of lyophilized peptide. To achieve a 100 mcg dose per 0.1 mL injection, add 5 mL of bacteriostatic water to the vial. This gives a concentration of 1,000 mcg per mL (1 mg/mL). At this concentration, a 100 mcg dose is 0.1 mL on a standard U-100 insulin syringe (10 units on the syringe scale). Always verify your own math with the specific vial amount and desired dose -- errors at this step cause significant under- or overdosing.
Signs a reconstituted peptide has degraded
- Cloudiness or visible particulate matter (aggregation)
- Discoloration from clear to yellow or brown (oxidation)
- Unexpected precipitate that does not dissolve on gentle swirling
- Unusual odor on opening a lyophilized vial (breakdown products)
None of these signs guarantees potency loss, and absence of visible changes does not guarantee potency. Without analytical testing, product quality in a reconstituted research peptide cannot be confirmed visually.
FAQ
Sources
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM 2021;384(11):989-1002. (STEP 1 trial, n=1,961)
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM 2022;387(3):205-216. (SURMOUNT-1 trial, n=2,539)
- Pi-Sunyer X, et al. "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management." NEJM 2015;373(1):11-22. (SCALE Obesity and Prediabetes)
- Wadden TA, et al. "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults with Overweight or Obesity: The STEP 3 Randomized Clinical Trial." JAMA 2021;325(14):1403-1413.
- Teichman SL, et al. "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults." J Clin Endocrinol Metab 2006;91(3):799-805.
- Svensson J, et al. "Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure." J Clin Endocrinol Metab 1998;83(2):362-9. (Ipamorelin-class reference for GH secretagogue physiology)
- Heffernan M, et al. "The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and beta(3)-AR Knock-Out Mice." Endocrinology 2001;142(12):5051-5057.
- Metabolic Pharmaceuticals. AOD-9604 Phase 3 Clinical Development Summary. Company disclosures, 2006-2007. (Phase 3 failure; no peer-reviewed publication of full trial; referenced in FDA GRAS notice GRN 000432)
- FDA GRAS Notice No. GRN 000432. AOD9604 as a Food Ingredient. US Food and Drug Administration, 2014.
- Falutz J, et al. "Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV." NEJM 2007;357(23):2359-70. (Tesamorelin in HIV lipodystrophy)
- Rubino DM, et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity: The STEP 4
Related peptide guides